Business Insider

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 ...

Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
The White House

Drug Czar Sara Carter Leads U.S. Delegation at the United Nations’ Commission on Narcotic Drugs in Vienna

Vienna, Austria – ONDCP Director Sara Carter addressed the 69 th session of the United Nations’ Commission on Narcotic Drugs (CND). The CND unites 53 member states in a shared cause—to monitor and ...
Hosted on MSN

TSA rules for medications in 2026 - avoid these common mistakes

TSA rules for traveling with medication have changed in 2026 — and getting them wrong can mean serious delays at security. In this video, we break down exactly what medications you’re allowed to bring ...
Healio

Non-Pharmacological Interventions

Pharmacological therapy for the management of hypoparathyroidism (hypoPT) can be supplemented by non-pharmacological intervention, primarily alterations to diet to increase intake of foods rich in ...
Healio

Pharmacological Interventions

Pharmacological options for hypoparathyroidism (hypoPT) management includes conventional therapy and parathyroid hormone (PTH) replacement. While these are the main options, other adjunctive ...